论文部分内容阅读
目的:探讨米非司酮治疗子宫肌腺症的临床效果。方法:子宫肌腺症患者90例,随机分为两组,对照组45例给予甲基睾丸治疗,观察组45例采取米非司酮治疗,就两组临床资料进行回顾性分析。结果:两组治疗后子宫体积及子宫肌瘤体积与治疗前比较均有所缩小,差异有统计学意义(P<0.05),其中观察组缩小幅度高于对照组,差异有显著统计学意义(P<0.05)。观察组停药后量不多、稀发月经4例,无阴道出血,半年内无绝经发生。对照组阴道少量出血3例,经期缩短,经量减少6例,停药后平均15d月经复潮。治疗后观察组贫血者血红蛋白为(11.8±5.3)g/L,对照组为(8.7±6.9)g/L,贫血纠正效果观察组优于对照组,差异有统计学意义(P<0.05)。观察组临床治愈率为95.6%,对照组治愈率为77.8%,差异有统计学意义(P<0.05)。结论:子宫肌腺症采用米非司酮治疗,可缩小子宫肌瘤体积及子宫体积,纠正贫血,诱导闭经,并发症发生率低,明显提高了治疗效果,具有非常重要的临床意义。
Objective: To investigate the clinical efficacy of mifepristone in the treatment of adenomyosis. Methods: Ninety patients with uterine adenomyosis were randomly divided into two groups. 45 cases in the control group were treated with methyltestis. 45 cases in the observation group were treated with mifepristone. The clinical data of two groups were retrospectively analyzed. Results: The volume of uterine fibroids and the volume of uterine fibroids in both groups decreased after treatment, the difference was statistically significant (P <0.05), and the reduction in observation group was higher than that in control group P <0.05). The observation group after stopping small amount of 4 cases of hair loss menstruation, no vaginal bleeding within six months without menopause. Control group, a small amount of vaginal bleeding in 3 cases, shortened menstrual period, the amount of reduction in 6 cases, after stopping the average 15d menstruation tide. After treatment, hemoglobin in anemia was (11.8 ± 5.3) g / L in the observation group and (8.7 ± 6.9) g / L in the control group, respectively. The anemia correction effect was better in the observation group than in the control group (P <0.05). The clinical cure rate was 95.6% in the observation group and 77.8% in the control group, the difference was statistically significant (P <0.05). Conclusion: Mifepristone treatment of uterine adenosis can reduce the volume of uterine fibroids and uterine volume, correct anemia, induce amenorrhea, the incidence of complications is low, and significantly improve the treatment effect, has very important clinical significance.